People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharma, Medical Devices, Pharmaceuticals, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2019 |
| Affinia Therapeutics Inc. | — | Pharma | Series D+ | $170.1M | $99.8M | 2020 |
| ShouTi Inc. | — | Biotechnology | Series D+ | $165.0M | $178.3M | 2019 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Caribou Biosciences, Inc. | — | Biotechnology | Series D+ | $141.0M | $3.8B | 2014 |
| Adela, Inc. | — | Biotechnology | Series C | $108.5M | $156.3M | 2021 |
| Zenflow, Inc. | — | Medical Devices | Series B | $75.3M | $116.7M | 2017 |
| Tetraphase Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $64.7M | $350.8M | 2009 |
| Farapulse, Inc. | — | Biotechnology | Series A | $36.3M | $433.8M | 2016 |
| Amphora Medical, Inc. | — | Healthtech | Series A | $23.8M | $248.6M | 2013 |
| Accuri Cytometers Inc | — | Other Health Care | Series A | $9.7M | $121.1M | 2009 |
| Basecamp Bio Inc. | — | Biotechnology | Series A | $9.0M | $229.7M | 2021 |
Robert Weisskoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Weisskoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew ElBardissi | 2 | 7 |
| David Grayzel | 2 | 6 |
| Raymond Stevens | 2 | 3 |
| Peter K Shagory | 2 | 2 |
| DAVID GARDNER | 1 | 20 |
| Michael Ross | 1 | 18 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Paul Brown | 1 | 12 |
| Jeffrey Williams | 1 | 10 |
| Robert Johnson | 1 | 9 |
| Ben Auspitz | 1 | 9 |
| Michael Liang | 1 | 9 |
| Timothy Petersen | 1 | 9 |
| Lawrence Miller | 1 | 8 |
| Daniel Lynch | 1 | 7 |
| Petpiboon Prasit | 1 | 7 |
| John G. Freund | 1 | 6 |
| Harry Wilcox | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.